ArticleFrontiers in oncology2026
Development of a nomogram for predicting axillary pathologic complete response after neoadjuvant therapy in clinically node-positive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable and accessible tools for estimating axillary pathologic complete response (ax-pCR) after neoadjuvant therapy (NAT) remain limited. This study evaluated whether routinely available biomarkers measured before and after NAT provide complementary information for ax-pCR prediction. Methods: We conducted a retrospective study of patients with clinically node-positive, non-metastatic breast cancer who underwent NAT followed by surgery. Clinicopathological characteristics, treatment information, serum albumin, and inflammatory indices measured before and after NAT were evaluated. Biomarker cutoffs were selected using the maximum Youden index. Variables with P<0.05 in univariable analyses were entered into multivariable logistic regression. A nomogram was constructed from variables that remained significant in the initial multivariable model. Discrimination, calibration, clinical net benefit and optimism-corrected performance were assessed using bootstrap resampling and decision-curve analysis. Results: Among 158 patients, ax-pCR occurred in 74 (46.8%). In the initial multivariable model, HER2 positivity and pre-NAT albumin ≥43.95 g/L were associated with higher odds of ax-pCR, whereas clinical stage III and post-NAT NLR ≥4.58 were associated with lower odds. The four-variable nomogram achieved an apparent AUC of 0.782 (95% CI, 0.708-0.851). At the maximum-Youden-index threshold, sensitivity was 74.3% (95% CI, 63.3%-82.9%) and specificity was 73.8% (95% CI, 63.5%-82.0%). After bootstrap correction, the AUC was 0.766, the calibration slope was 0.908 and the Brier score was 0.200. Decision-curve analysis suggested potential net benefit across a range of threshold probabilities. Conclusion: Clinical characteristics and blood-based biomarkers measured before and after NAT provided complementary information for ax-pCR estimation. The nomogram showed moderate discrimination and reasonable internal calibration. External validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.